Dual receptor agonism
Simultaneous GIP and GLP-1 receptor engagement produces a signalling profile studied for additive metabolic effects.
- GIP receptor activation
- GLP-1 receptor activation
- Glucose-dependent insulin release
≥99% Purity
Trezepitide GLP-2
Dual Incretin Receptor Studies
$90.00$67.50/vial with BOGO
Quantity1
Buy 1 Get 1 50% off · auto-appliedAdd 2+ items to cart — every second vial is 50% offOffer Ends 9/15
Same day / next business day dispatch
Free Shipping on orders over $200
Secure Checkout
Third-Party Tested
Money-Back Guarantee
PassedSterility & Endotoxins
PassedNet Content & Purity
Researchers also added
About this compound
Trezepitide is a dual GIP and GLP-1 receptor agonist peptide studied for combined incretin signalling. The dual-agonist class has been characterised in the literature for its effects on insulin secretion, gastric emptying, and adipose-tissue substrate handling relative to selective GLP-1 agonists.
Dual GIP / GLP-1 receptor agonist peptide
- Formula
- C225H348N48O68
- Molecular weight
- 5109.7 g/mol
- CAS / ID
- 2023788-19-2
- Form
- Lyophilized powder
0%
Body-weight change
72-week dual-agonist programme
0
Receptor targets
GIP and GLP-1
0+
Indexed studies
Dual incretin literature
0
Amino acids
Synthetic peptide backbone
How It WorksIncretin signalling Adipose biology
How Trezepitide GLP-2 works
The pathways Trezepitide GLP-2 acts on — and what each one does. Signalling pathways studied in preclinical models · illustrative.
Lipid handling
GIP receptor signalling in adipocytes has been examined for its role in lipid buffering and insulin sensitivity.
- Adipocyte lipid uptake
- Insulin-sensitivity markers
- Reported lean-mass retention
Uses & applicationsMetabolic Glycaemic
What Trezepitide GLP-2 is researched for
The main areas Trezepitide GLP-2 is being studied for — and the study-reported figures behind them.
Body-composition research
Dual agonists evaluated across 72-week randomised programmes for weight trajectory.
NEJM 2022
Glucose control
Compared against selective GLP-1 agonists for HbA1c response.
NEJM 2021
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
- Body-weight change (72 wk)−20.9%
- HbA1c reductionReduced
- Fasting insulinReduced
Figures are representative of published research findings and shown for reference.
Third-Party Verified
Independently tested. Verifiably pure.
Every batch of Trezepitide GLP-2 is sent to an accredited independent laboratory before it ships. Here is what we screen for.
- HPLC Purity AnalysisConfirms the peptide is ≥99% pure
- Mass SpectrometryVerifies the exact molecular identity
- Heavy Metals ScreeningLead, arsenic, cadmium & mercury — Pass
- Endotoxins (LAL)Bacterial endotoxin levels — Pass
- Sterility TestingNo microbial contamination — Pass
- Net Peptide ContentActual peptide mass per vial verified
Compound Information
Full specification
| Compound | Trezepitide |
|---|---|
| Molecular formula | C225H348N48O68 |
| Molecular weight | 5109.7 g/mol |
| CAS number | 2023788-19-2 |
| Purity (HPLC) | ≥99% |
| Vial size | 10mg |
| Physical form | Lyophilized white powder |
| Storage | -20 °C, protected from light |
| Reconstitution | Bacteriostatic water |
| Intended use | Laboratory research only — not for human consumption |
FAQ
Common questions about Trezepitide GLP-2
Every Trezepitide lot is assayed by HPLC to ≥99% purity, with mass-spectrometry identity confirmation. The certificate of analysis for your lot is available in the COA library.
Store lyophilized vials at -20 °C protected from light. Once reconstituted with bacteriostatic water, keep refrigerated at 2–8 °C and use within the window described in your protocol.
No. This compound is supplied strictly as a reference material for in-vitro and laboratory research. It is not a drug, supplement, or food, and it is not intended for human or animal consumption.
Yes. Independent third-party laboratories run identity and purity panels on each production lot, and the signed report is archived by lot number.
Published Literature
Peer-reviewed literature
Independent published research indexed from PubMed and peer-reviewed journals — not Zorva Lab claims.
For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Back to catalog